Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 23 April, 2010

Lipoxen PLC

Director/PDMR Shareholding

RNS Number : 6633K
Lipoxen PLC
23 April 2010
 



For immediate release

23 April 2010

 

 

Lipoxen PLC

('Lipoxen' or 'the Company')

 

DIRECTOR DEALING

 

Lipoxen PLC (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is pleased to announce that further to the announcement released on 1 April 2010, that the Company has raised £1.2 million through a non pre-emptive issue of shares (the "Fundraising"), certain directors have acquired ordinary shares of 0.5 pence each (the "New Ordinary Shares"). Details of the director dealings are set out in the table below:

 

Name

Date

Shares acquired

Total interest

% of total issued share capital

Sir Brian Richards

1 April 2010

1,071,429

2,262,606

1.32

Scott Maguire

1 April 2010

535,714

1,301,362

0.76

Colin Hill

1 April 2010

535,714

1,675,420

0.97

  

- Ends -

 

For further information please contact:

 

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång

Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon / Catherine Breen

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKMGZDVZZGGZM